Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page
- Check6 days agoChange DetectedNIH funding entries for 2017 and 2023 were added to the page. The revision history now shows v3.6.6, and the previous v3.6.5 entry was removed.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe Plain Language Summary section was removed from the study record page, eliminating the patient-friendly overview of the trial and its purpose.SummaryDifference0.0%

- Check27 days agoChange Detected- The page revision has been updated to v3.6.5. The previous revision indicator v3.6.4 has been replaced.SummaryDifference0.0%

- Check34 days agoChange DetectedThe study record now includes new registry identifiers (UTN and EU CT) and adds data-sharing resources: a PDF with data-access procedures and an external data-sharing site, while older EngageZone links were removed. These changes place the trial's data-sharing framework and identifiers into current reference points for researchers and stakeholders.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a new build of the underlying documentation/system. This change is an internal version update rather than a visible content update.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision: v3.6.3 was added and Revision: v3.6.2 was removed. This indicates the page's revision history has been updated.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.